Author

Simon J. Harrison

h-index 14 View on Semantic Scholar

We have 3 of 60 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Forimtamig, a GPRC5DxCD3 bispecific antibody with a novel 2:1 format, in relapsed/refractory multiple myeloma.

SC forimtamig demonstrated potent and durable activity in RRMM, which could be enhanced with a condensed step-up schedule, highlighting the narrow therapeutic window for GPRC5D as a target for T-cell-engaging bispecific antibodies.

Anna Caroline Hasselbalch, Simon J. Harrison, Salomon Manier et al. · Blood Advances · 0 citations

Open access Sep 2026

Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel.

The clinical utility of routine monitoring of chimeric antigen receptor (CAR) T-cell expansion post-infusion remains controversial. We conducted a retrospective analysis of a prospectively collected cohort of 176 patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-ce...

Brydon Panozzo, S. Robinson, A. Minson et al. · British Journal of Haematolo... · 0 citations

Open access Sep 2026

T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma.

T-cell bispecific (TCB) therapies have demonstrated promising therapeutic efficacies for patients with relapsed/refractory multiple myeloma. However, responses are transient and essentially all patients eventually relapse. Cytokine release syndrome and other on-target off-tumor toxicities are common. Together, these ch...

I. Dekhtiarenko, Jan Attig, I. Lelios et al. · Blood Advances · 0 citations